Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
Open Access
- 1 December 2020
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 12705-12720
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of death in the Western world, and it is estimated to become the second leading cause of tumour-related mortality in the next 10 years. Among pancreatic cancers, ductal adenocarcinomas are by far the most common, characterised by a challenging diagnosis due to the lack of initial and pathognomonic clinical signs. In this scenario, non-metastatic locally advanced pancreatic cancer (LAPC) accounts for a large proportion of all new pancreatic ductal adenocarcinoma diagnoses. There is no consensus on a common definition of LAPC. Still, it usually includes tumours that are not resectable due to vascular involvement. As of today, treatment is limited, and the prognosis is very unfavourable. Curative-intent surgery remains the gold-standard even if often jeopardized by vascular involvement. Continuing progress in our understanding of LAPC genetics and immunology will permit the development of different treatments, targeted or combined, including radiation therapy, hadrontherapy, targeted immunotherapies or new chemotherapies. A multidisciplinary approach combining various fields of expertise is essential in aiming to limit disease progression as well as patient outcome. Using a narrative literature review approach, the manuscript explores the most up-to-date knowledge concerning locally advanced pancreatic ductal adenocarcinoma management.Keywords
This publication has 126 references indexed in Scilit:
- Obesity and pancreatic cancer: Overview of epidemiologic evidence and biologic mechanismsMolecular Carcinogenesis, 2011
- Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4)Annals of Oncology, 2011
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trialsSurgery, 2011
- Anthropometric Measures, Body Mass Index, and Pancreatic CancerArchives of internal medicine (1960), 2010
- Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohortsCancer Causes & Control, 2010
- Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis From the Pancreatic Cancer Cohort ConsortiumAmerican Journal of Epidemiology, 2009
- Tumors of the Ampulla of Vater: Histopathologic Classification and Predictors of SurvivalJournal of the American College of Surgeons, 2008
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnnals of Oncology, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- Advances in counselling and surveillance of patients at risk for pancreatic cancer: Table 1Gut, 2007